Οριακή μεταβολή καινοτομίας – το μέλλον των ελληνικών φαρμακευτικών εταιρειών: απόψεις των εμπλεκομένων και στρατηγικές αντιμετώπισης
Incremental innovation - the future of greek pharmaceutical industry: stakeholders’ opinion and implementation strategies
KeywordsΟριακή μεταβολή καινοτομίας ; Έρευνα και ανάπτυξη ; Φαρμακοβιομηχανία ; Φάρμακα ; Incremental innovation ; Research and development ; Pharmaceutical industry ; Drugs ; Me-too φάρμακα ; Follow-on φάρμακα
This dissertation is a research work that deals with concept of incremental innovation in the pharmaceutical industry. Following the financial crisis of 2008, Greece faces serious fiscal problems associated with high public debt and a deficit. Due to their significant contribution to public sector spending, part of the efforts to reduce public spending related to the focus on pharmaceutical markets. Over the past century, the pharmaceutical industry was responsible for thousands of new drugs, based on hundreds of thousands of smaller borderline innovations. However, critics were extremely malignant in what they refer to as "me-too" or "follow-on" because they claim to be just copies of already existing molecules. However, in fact most pharmaceutical innovations are evolving. Additionally, companies often discover the evolution of how innovative their new drug is in reality. In any case, increased improvements in treatment can bring great benefits to patients and health care systems. Because innovation is the life blood of the pharmaceutical industry. In the case of Greece, research and development (R & D) is limited to phases 3 and 4 of the clinical trials, and there is no possibility of finding new pioneering drugs. To a large extent, the Greek pharmaceutical industry produces "generic" drugs, but their profits are very low, especially after mandatory rebates and rebates. Therefore, increased innovation products, which do not require research because they are considered innovative and priced as prototypes, offer the Greek pharmaceutical industry the opportunity to significantly increase its profitability and ensure its future. Our analysis shows that the incremental innovation is the way for the next day of the Greek pharmaceutical industry.